Comparing asthma treatment in elderly versus younger patients

J Haughney, M Aubier, L Jørgensen, J Ostinelli, O Selroos, C P van Schayck, R Buhl

Research output: Contribution to journalArticle

13 Citations (Scopus)

Abstract

A randomised 6-month study compared two maintenance doses of budesonide/formoterol (Symbicort® Turbuhaler® (h) maintenance and reliever therapy (Symbicort SMART®), 160/4.5 μg 1 × 2 and 2 × 2, in 8053 asthmatics with symptoms despite treatment with inhaled corticosteroids ± inhaled long-acting β2-agonists. This analysis compared response to the two treatments in elderly patients, ≥ 65 years, with that in younger patients. Elderly patients with early- or late-onset asthma were also compared. Elderly patients had lower post-bronchodilator FEV1 percentage predicted normal at baseline than younger patients (85.6% vs. 91.0%, respectively). The elderly had more exacerbations and risk of first severe exacerbation was increased by 55.3% (hazard ratio 1.553; 95% confidence interval: 1.249-1.931, p < 0.0001). However, no differences in exacerbations were seen between 1 × 2 or 2 × 2 budesonide/formoterol maintenance and reliever therapy treatment in the elderly. Five-item Asthma Control Questionnaire (ACQ-5) scores improved equally in the two age groups. Changes in mean ACQ-5 scores between 1 × 2 and 2 × 2 were significant in both age groups but not clinically relevant (≥ 65 years, 0.12; p = 0.018; <65 years, 0.09; p < 0.0001). Elderly patients with early- and late-onset asthma responded equally well to treatment. Budesonide/formoterol maintenance and reliever therapy (1 × 2 or 2 × 2) is an effective, well-tolerated and practical treatment concept in elderly and younger asthmatic patients.

Original languageEnglish
Pages (from-to)838-845
Number of pages8
JournalRespiratory Medicine
Volume105
Issue number6
DOIs
Publication statusPublished - Jun 2011

Fingerprint

Asthma
Budesonide
Maintenance
Therapeutics
Age Groups
Bronchodilator Agents
Adrenal Cortex Hormones
Confidence Intervals
Formoterol Fumarate

Keywords

  • administration, inhalation
  • adult
  • aged
  • asthma
  • bronchodilator agents
  • budesonide
  • disease progression
  • dose-response relationship, drug
  • drug therapy, combination
  • ethanolamines
  • female
  • formoterol fumarate
  • humans
  • male
  • quality of life
  • surveys and questionnaires
  • treatment outcome

Cite this

Haughney, J., Aubier, M., Jørgensen, L., Ostinelli, J., Selroos, O., van Schayck, C. P., & Buhl, R. (2011). Comparing asthma treatment in elderly versus younger patients. Respiratory Medicine, 105(6), 838-845. https://doi.org/10.1016/j.rmed.2011.02.011

Comparing asthma treatment in elderly versus younger patients. / Haughney, J; Aubier, M; Jørgensen, L; Ostinelli, J; Selroos, O; van Schayck, C P; Buhl, R.

In: Respiratory Medicine, Vol. 105, No. 6, 06.2011, p. 838-845.

Research output: Contribution to journalArticle

Haughney, J, Aubier, M, Jørgensen, L, Ostinelli, J, Selroos, O, van Schayck, CP & Buhl, R 2011, 'Comparing asthma treatment in elderly versus younger patients', Respiratory Medicine, vol. 105, no. 6, pp. 838-845. https://doi.org/10.1016/j.rmed.2011.02.011
Haughney J, Aubier M, Jørgensen L, Ostinelli J, Selroos O, van Schayck CP et al. Comparing asthma treatment in elderly versus younger patients. Respiratory Medicine. 2011 Jun;105(6):838-845. https://doi.org/10.1016/j.rmed.2011.02.011
Haughney, J ; Aubier, M ; Jørgensen, L ; Ostinelli, J ; Selroos, O ; van Schayck, C P ; Buhl, R. / Comparing asthma treatment in elderly versus younger patients. In: Respiratory Medicine. 2011 ; Vol. 105, No. 6. pp. 838-845.
@article{fa6a3719bf7b4c13ada8676697b5880f,
title = "Comparing asthma treatment in elderly versus younger patients",
abstract = "A randomised 6-month study compared two maintenance doses of budesonide/formoterol (Symbicort{\circledR} Turbuhaler{\circledR} (h) maintenance and reliever therapy (Symbicort SMART{\circledR}), 160/4.5 μg 1 × 2 and 2 × 2, in 8053 asthmatics with symptoms despite treatment with inhaled corticosteroids ± inhaled long-acting β2-agonists. This analysis compared response to the two treatments in elderly patients, ≥ 65 years, with that in younger patients. Elderly patients with early- or late-onset asthma were also compared. Elderly patients had lower post-bronchodilator FEV1 percentage predicted normal at baseline than younger patients (85.6{\%} vs. 91.0{\%}, respectively). The elderly had more exacerbations and risk of first severe exacerbation was increased by 55.3{\%} (hazard ratio 1.553; 95{\%} confidence interval: 1.249-1.931, p < 0.0001). However, no differences in exacerbations were seen between 1 × 2 or 2 × 2 budesonide/formoterol maintenance and reliever therapy treatment in the elderly. Five-item Asthma Control Questionnaire (ACQ-5) scores improved equally in the two age groups. Changes in mean ACQ-5 scores between 1 × 2 and 2 × 2 were significant in both age groups but not clinically relevant (≥ 65 years, 0.12; p = 0.018; <65 years, 0.09; p < 0.0001). Elderly patients with early- and late-onset asthma responded equally well to treatment. Budesonide/formoterol maintenance and reliever therapy (1 × 2 or 2 × 2) is an effective, well-tolerated and practical treatment concept in elderly and younger asthmatic patients.",
keywords = "administration, inhalation, adult, aged, asthma, bronchodilator agents, budesonide, disease progression, dose-response relationship, drug, drug therapy, combination, ethanolamines, female, formoterol fumarate, humans, male, quality of life, surveys and questionnaires, treatment outcome",
author = "J Haughney and M Aubier and L J{\o}rgensen and J Ostinelli and O Selroos and {van Schayck}, {C P} and R Buhl",
note = "Copyright {\circledC} 2011 Elsevier Ltd. All rights reserved.",
year = "2011",
month = "6",
doi = "10.1016/j.rmed.2011.02.011",
language = "English",
volume = "105",
pages = "838--845",
journal = "Respiratory Medicine",
issn = "0954-6111",
publisher = "Elsevier",
number = "6",

}

TY - JOUR

T1 - Comparing asthma treatment in elderly versus younger patients

AU - Haughney, J

AU - Aubier, M

AU - Jørgensen, L

AU - Ostinelli, J

AU - Selroos, O

AU - van Schayck, C P

AU - Buhl, R

N1 - Copyright © 2011 Elsevier Ltd. All rights reserved.

PY - 2011/6

Y1 - 2011/6

N2 - A randomised 6-month study compared two maintenance doses of budesonide/formoterol (Symbicort® Turbuhaler® (h) maintenance and reliever therapy (Symbicort SMART®), 160/4.5 μg 1 × 2 and 2 × 2, in 8053 asthmatics with symptoms despite treatment with inhaled corticosteroids ± inhaled long-acting β2-agonists. This analysis compared response to the two treatments in elderly patients, ≥ 65 years, with that in younger patients. Elderly patients with early- or late-onset asthma were also compared. Elderly patients had lower post-bronchodilator FEV1 percentage predicted normal at baseline than younger patients (85.6% vs. 91.0%, respectively). The elderly had more exacerbations and risk of first severe exacerbation was increased by 55.3% (hazard ratio 1.553; 95% confidence interval: 1.249-1.931, p < 0.0001). However, no differences in exacerbations were seen between 1 × 2 or 2 × 2 budesonide/formoterol maintenance and reliever therapy treatment in the elderly. Five-item Asthma Control Questionnaire (ACQ-5) scores improved equally in the two age groups. Changes in mean ACQ-5 scores between 1 × 2 and 2 × 2 were significant in both age groups but not clinically relevant (≥ 65 years, 0.12; p = 0.018; <65 years, 0.09; p < 0.0001). Elderly patients with early- and late-onset asthma responded equally well to treatment. Budesonide/formoterol maintenance and reliever therapy (1 × 2 or 2 × 2) is an effective, well-tolerated and practical treatment concept in elderly and younger asthmatic patients.

AB - A randomised 6-month study compared two maintenance doses of budesonide/formoterol (Symbicort® Turbuhaler® (h) maintenance and reliever therapy (Symbicort SMART®), 160/4.5 μg 1 × 2 and 2 × 2, in 8053 asthmatics with symptoms despite treatment with inhaled corticosteroids ± inhaled long-acting β2-agonists. This analysis compared response to the two treatments in elderly patients, ≥ 65 years, with that in younger patients. Elderly patients with early- or late-onset asthma were also compared. Elderly patients had lower post-bronchodilator FEV1 percentage predicted normal at baseline than younger patients (85.6% vs. 91.0%, respectively). The elderly had more exacerbations and risk of first severe exacerbation was increased by 55.3% (hazard ratio 1.553; 95% confidence interval: 1.249-1.931, p < 0.0001). However, no differences in exacerbations were seen between 1 × 2 or 2 × 2 budesonide/formoterol maintenance and reliever therapy treatment in the elderly. Five-item Asthma Control Questionnaire (ACQ-5) scores improved equally in the two age groups. Changes in mean ACQ-5 scores between 1 × 2 and 2 × 2 were significant in both age groups but not clinically relevant (≥ 65 years, 0.12; p = 0.018; <65 years, 0.09; p < 0.0001). Elderly patients with early- and late-onset asthma responded equally well to treatment. Budesonide/formoterol maintenance and reliever therapy (1 × 2 or 2 × 2) is an effective, well-tolerated and practical treatment concept in elderly and younger asthmatic patients.

KW - administration, inhalation

KW - adult

KW - aged

KW - asthma

KW - bronchodilator agents

KW - budesonide

KW - disease progression

KW - dose-response relationship, drug

KW - drug therapy, combination

KW - ethanolamines

KW - female

KW - formoterol fumarate

KW - humans

KW - male

KW - quality of life

KW - surveys and questionnaires

KW - treatment outcome

U2 - 10.1016/j.rmed.2011.02.011

DO - 10.1016/j.rmed.2011.02.011

M3 - Article

VL - 105

SP - 838

EP - 845

JO - Respiratory Medicine

JF - Respiratory Medicine

SN - 0954-6111

IS - 6

ER -